FDA Inspection 1304150 — NEOLPHARMA, INC.

NEOLPHARMA, INC. — FEI 3009993897

The FDA completed an inspection of NEOLPHARMA, INC. on March 10, 2026 in Caguas, PR. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 2 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
March 10, 2026
Fiscal Year
2026
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Caguas, PR (United States)

Citations

IDCFRDescription
110521 CFR 211.22(d)Procedures not in writing, fully followed
355921 CFR 211.56(a)Sanitation--buildings not clean, free of infestation